Navigation Links
Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients

-- 100 percent response rate achieved with VELCADE, lenalidomide and dexamethasone

KOS, Greece, June 28 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported on the presentation of results from four clinical trials of VELCADE based therapies that showed consistently high survival and complete remission / complete response(1) (CR) rates in newly diagnosed multiple myeloma (MM) patients. These data were presented at the prestigious 11th International Myeloma Workshop (IMW) in Kos, Greece. Highlights included:

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

-- VELCADE, melphalan and prednisone (VMP) demonstrated a CR(1) rate of 43 percent, the strongest rate ever reported for a melphalan prednisone combination therapy. At 38 months, 85 percent of patients were alive. This is the highest reported three-year survival rate in the front-line treatment setting.

-- VELCADE, adriamycin and dexamethasone (referred to as VcAD or PAD) showed a CR(1) rate of 29 percent prior to stem cell transplantation (SCT), which further improved to 57 percent following SCT. At one year, 100 percent of patients were alive, and at two years, 95 percent of patients were alive. This is the highest reported two-year survival rate in the front-line treatment setting. Median overall survival (OS) has not yet been reached after four years.

-- VELCADE, DOXIL(R) (pegylated liposomal doxorubicin) and dexamethasone (VDD) showed a CR(1) rate of 43 percent prior to SCT, which increased to 65 percent following SCT. At 16 months, 100 percent of patients were alive.

-- VELCADE, lenalidomide and dexamethasone (VRD) showed an overall res
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:9/19/2014)... 2014 Five MinuteClinic walk-in medical clinics are opening inside ... area. Three clinics opened in Memphis and ... will be added in Springfield on September ... is expected to open October 22.  MinuteClinic is the largest and ... United States . The Memphis ...
(Date:9/19/2014)... Sept. 19, 2014 Larry J. Merlo , ... ), will speak before the National Press Club in ... company,s recent move to stop selling tobacco products and its ... of health. "Dramatic changes in our health care ... and government," Merlo has said. "CVS Health has a truly ...
(Date:9/19/2014)... , September 19, 2014 ... Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry ... (Tray-style, Manifold, & Rotary) & Geography - Global ... defines and segments the lyophilization market on the ... analyses and projections of the market size of ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
... Streamline Health Solutions, Inc. (Nasdaq: STRM ... for hospitals, announced today that two of its clients, ... North Carolina, contracted with Streamline Health to implement new ... began the beta phase of integration earlier this year, ...
... July 28, 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: ... financial results for the company,s second quarter ended June 30, ... Aug. 11, 2011. The Pacira management team will host a ... and upcoming developments on Thursday, Aug. 11, 2011 at 9 ...
Cached Medicine Technology:Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 2Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 3Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 4Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call 2
(Date:9/19/2014)... Centre for Accident Research & Road Safety - Queensland ... in Transport Conference (OSIT) which is being held on ... Blackman, a CARRS-Q road safety researcher, said speed limit ... limits and related traffic controls remained in place at ... If people are asked to slow down at roadwork ...
(Date:9/19/2014)... Lifeinsure.biz has released a new ... can be purchased without medical examinations. , Life ... a life insurance policy more advantageous. Clients can read ... extra options available for a no medical exam life ... required is simple to purchase, however it is more ...
(Date:9/19/2014)... 19, 2014 Outsourcing services provider Profit By ... US IT conglomerate to provide HR outsourcing services in India. ... an exclusive partner and will act as a talent acquisition ... deploy over 120 personnel across 3 locations in India in ... , "This is a significant win for us and we ...
(Date:9/19/2014)... 2014 Kyrgyzstan has one of ... To reduce the burden of tuberculosis (TB) and ... Kyrgyz Republic, Abt Associates has been awarded the ... Program under a five-year cooperative agreement with total ... support universal and equitable access to high-quality TB ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
Breaking Medicine News(10 mins):Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:New Project Aims to Reduce Burden of Tuberculosis in the Kyrgyz Republic 2Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2
... disease, rheumatoid arthritis (RA) is characterized by persistent inflammation ... Beyond loss of mobility, sufferers face a high risk ... contributing to the development of RA, tumor necrosis factor ... Inhibition of TNFa has opened promising new treatment ...
... DALLAS Feb. 28, 2008 UT Southwestern Medical ... operation requiring only a single incision in the bellybutton ... It is the first such operation in North Texas. ... Homero Rivas, assistant professor of surgery, who completed the ...
... Actavis Group, the,international generic pharmaceuticals company, has ... Food & Drug Administration., The four products ... equivalent of,Bontril(R) tablets by Valeant Pharmaceuticals, are indicated ... of Phendimetrazine tartrate tablets,had annual sales of US$3.1 ...
... 40.6%, ETHEX Revenue Up 57.8% for Third Quarter, Up ... Revenue Up 16.6% for Third Quarter, Up 15.2% ... KV Pharmaceutical Company,(NYSE: KVa/KVb) today reported preliminary financial results ... 2008 ended December 31, 2007. The,results reflected continued acceleration ...
... the Robert Wood Johnson Foundation, has launched the Network for ... study health care disparities affecting minorities with chronic diseases. ... a new generation of researchers with an expertise in health ... to be directed by Dr. Michael Rodrguez, associate professor of ...
... drop in a severe form of the disorder, , , WEDNESDAY, Feb. ... decreasing, and a more severe form of the disease caused by ... Those are the two main findings from a Massachusetts study that ... and 35 babies a year before 2003 to less than 20 ...
Cached Medicine News:Health News:Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients 2Health News:Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients 3Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 2Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 3Health News:Actavis Extends Portfolio With Four New Products in the U.S. 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 3Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 4Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 5Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 6Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 7Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 8Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 9Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 10Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 11Health News:UCLA launches network to study health care disparities affecting minorities 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: